An observational study in Schizophrenia, sponsored by Janssen-Cilag Farmaceutica Ltda.. Completed at 1 site in Portugal. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-04-27.
Sponsored by Janssen-Cilag Farmaceutica Ltda. (part of Johnson & Johnson) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 206 studies in Schizophrenia by Johnson & Johnson — 2 open to participants now, 2 under way, 1 of them phase 3. Schizophrenia · Johnson & Johnson.
Among the 206 studies in Schizophrenia by Johnson & Johnson, this one is the 28th largest by enrollment of the 30 observational ones that give a count, is one of 4 that started in 2018, is one of 30 observational ones, and was the 196th registered.
3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →2 of the 206 studies in Schizophrenia by Johnson & Johnson are open now, in 3 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States
Ages 18–60
Intra-Cellular Therapies, Inc. · Sites in United States, Colombia, Serbia
Ages 5–17
By country, each count listing its studies:
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
206 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 43 · Phase 2 12 · Phase 3 74 · Phase 4 47
First in 1996; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 55 is below the median of 178 across 508 observational studies indexed under Schizophrenia.
Median enrollment 165 across the 176 interventional studies, 541 across the 30 observational. Of the 203 that completed or were terminated, 57 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen-Cilag Farmaceutica Ltda., one of the names counted as Johnson & Johnson. Under that name alone:
Janssen-Cilag Farmaceutica Ltda. is the lead sponsor of 13 studies on the registry; 2 are open to participants now.
1 of the studies in Schizophrenia by Johnson & Johnson that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07615426Janssen Research & Development, LLCA Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia | 2027-06-21 |
Add it to your calendar (.ics) → With an account.
Among the 206 studies in Schizophrenia by Johnson & Johnson, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the mean number of schizophrenia-related hospital admissions, in adult participants with schizophrenia, occurred during 12 months before and 12 months after initiation of Paliperidone Palmitate 1-month formulation treatment.
The study population will include ambulatory participants diagnosed with schizophrenia that switched from oral antipsychotics (OAPs) to paliperidone palmitate 1-month formulation (PP1M), and with available information concerning the annual schizophrenia-related hospitalizations before and after initiation of PP1M treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants diagnosed with schizophrenia who switched from oral antipsychotics (OAPs) to Paliperidone Palmitate 1-month formulation (PP1M), with available information concerning the annual schizophrenia-related hospitalizations before and after initiation of PP1M treatment, and who switched to PP1M at least 6-months after it was available for reimbursement in Portugal will be observed. The primary data source for this study will be the medical records of each participant.
Drug: Oral Antipsychotics (OAPs) · Drug: Paliperidone Palmitate 1-Month Formulation (PP1M)
No study treatment will be administered as a part of this study. Participants will receive OAPs (such as olanzapine, risperidone, paliperidone, aripiprazole or quetiapine) as per their usual clinical practice.
No study treatment will be administered as a part of this study. Participants will receive PP1M as per their usual clinical practice.
Mean Number of Schizophrenia-Related Hospital Admissions Occurred During 12 Months of OAP Treatment Prior to PP1M Treatment
Mean number of schizophrenia-related hospital admissions occurred during 12 months of oral antipsychotics (OAP) treatment prior to initiation of Paliperidone Palmitate 1-Month Formulation (PP1M) treatment will be reported. Mean number of Schizophrenia-related hospital admissions will be calculated as: number of hospital admissions divided by total number of participants.
Time frame: Approximately 12 months
Mean Number of Schizophrenia-Related Hospital Admissions Occurred During 12 Months After Initiation of PP1M Treatment
Mean number of schizophrenia-related hospital admissions occurred during 12 months after initiation of PP1M treatment will be reported. Mean number of Schizophrenia-related hospital admissions will be calculated as: number of hospital admissions divided by total number of participants.
Time frame: Approximately 12 months
Mean Change of Schizophrenia-Related Hospital Admissions Between Periods
Mean change of schizophrenia-related hospital admissions occurred between periods (during 12 months of OAP treatment prior and 12 months after initiation of PP1M treatment) will be reported.
Time frame: Approximately 24 months
Mean Number of Hospital Admissions Occurred During 12 Months of OAP Treatment Prior to PP1M and During 12 Months After Initiation of PP1M Treatment for the Subgroup of Participants that Completed 12 Months of PP1M Treatment
Mean number of hospital admissions occurred during 12 months of OAP treatment prior to PP1M and during 12 months after initiation of PP1M treatment for the subgroup of participants that completed 12 months of PP1M treatment will be reported. Mean number of hospital admissions will be calculated as: number of hospital admissions divided by total number of participants.
Time frame: Approximately 24 months
Mean Change of Hospital Admissions Between Periods for the Subgroup of Participants that Completed 12 Months of PP1M Treatment
Mean change of hospital admissions occurred for the subgroup of participants that completed 12 months of PP1M between periods (during 12 months of OAP treatment prior and after initiation of PP1M treatment) will be reported.
Time frame: Approximately 24 months
Mean Number of Hospital Admissions Occurred During 12 Months of OAP Treatment Prior to PP1M and During 12 Months After Initiation of PP1M Treatment for the Subgroup of Participants that Discontinued Before Completing 12 Months of PP1M Treatment
Mean number of hospital admissions occurred during 12 months of OAP treatment prior to PP1M and during 12 months after initiation of PP1M treatment for the subgroup of participants that discontinued before completing 12 months of PP1M treatment will be reported. Mean number of hospital admissions will be calculated as: number of hospital admissions divided by total number of participants.
Time frame: Approximately 24 months
Mean Change of Hospital Admissions Between Periods for the Subgroup of Participants That Discontinued Before Completing 12 Months of PP1M Treatment
Mean change of hospital admissions occurred for the subgroup of participants that discontinued before completing 12 months of PP1M treatment between periods (during 12 months of OAP treatment prior and after initiation of PP1M treatment) will be reported.
Time frame: Approximately 24 months
Mean Length of Hospitalizations
Mean length of hospitalizations occurred during 12 months after initiation of OAP treatment and the mean length of hospitalizations occurred during 12 months after initiation of PP1M treatment will be reported.
Time frame: Approximately 24 months
Mean Change in Length of Hospitalizations Between Periods
Mean change in length of hospitalizations between periods (occurred during 12 months after initiation of OAP treatment and during 12 months after initiation of PP1M treatment) will be reported.
Time frame: Approximately 24 months
Mean Cumulative Length of Hospitalizations
The mean cumulative length of hospitalizations occurred during 12 months after initiation of OAP treatment and the mean length of hospitalizations occurred during 12 months after initiation of PP1M treatment will be reported.
Time frame: Approximately 24 months
Mean Change in Cumulative Length of Hospitalizations Between Periods
Mean change in cumulative length of hospitalizations between periods (occurred during 12 months after initiation of OAP treatment and during 12 months after initiation of PP1M treatment) will be reported.
Time frame: Approximately 24 months
Hospitalization Rate per Patient-Years
The hospitalization rate per patient-year will be calculated as: Hospitalization rate per patient-years = Number of hospitalizations in the treatment period divided by total follow-up time in the treatment period where the total follow-up time corresponds to the cumulative follow-up time of all included participants in the treatment period.
Time frame: Approximately 24 months
Mean Number of Emergency Psychiatric Visits
The mean number of emergency psychiatric visits occurred during 12 months of OAP treatment prior to PP1M and the mean number of emergency psychiatric visits occurred during 12 months after initiation of PP1M treatment will be reported.
Time frame: Approximately 24 months
Mean Change in Emergency Psychiatric Visits Between Periods
Mean change in emergency psychiatric visits between periods (occurred during 12 months of OAP treatment prior to PP1M and during 12 months after initiation of PP1M treatment) will be reported.
Time frame: Approximately 24 months
Percentage of Participants Hospitalized
Percentage of participants hospitalized during 12 months of OAP treatment prior to PP1M and the percentage of participants hospitalized during 12 months after initiation of PP1M treatment will be reported.
Time frame: Approximately 24 months
Change in Percentages of Participants Hospitalized Between Periods (Hospitalization Reduction Percentage)
Change in percentage of participants hospitalized between periods (percentage of participants hospitalized during 12 months of OAP treatment prior to PP1M and the percentage of participants hospitalized during 12 months after initiation of PP1M treatment) will be reported.
Time frame: Approximately 24 months
Percentage of Outpatient Psychiatric Consultations
Percentage of outpatient psychiatric consultations occurred during 12 months of OAP treatment prior to PP1M and the percentage of outpatient psychiatric consultations occurred during 12 months after initiation of PP1M treatment will be reported.
Time frame: Approximately 24 months
Change in Percentage of Outpatient Psychiatric Consultations Between Periods
Change in percentage of outpatient psychiatric consultations between periods (occurred during 12 months of OAP treatment prior to PP1M and during 12 months after initiation of PP1M treatment) will be reported.
Time frame: Approximately 24 months
Percentage of Relapse with Different Causes
Percentage of relapse with different causes occurred during 12 months of OAP treatment prior to PP1M and the percentage of relapse occurred during 12 months after initiation of PP1M treatment will be reported.
Time frame: Approximately 24 months
Change in Percentages of Relapse Between Periods with Different Causes
Change in percentage of relapse between periods with different causes (occurred during 12 months of OAP treatment prior to PP1M and during 12 months after initiation of PP1M treatment) will be reported.
Time frame: Approximately 24 months
Percentage of Participants who Discontinued PP1M Treatment with Different Reasons for Discontinuation Before and After Completing 12 Months of Treatment
Percentage of participants who discontinued PP1M treatment with different reasons for discontinuation (such as, lack of efficacy, tolerability issues or other) before and after completing 12 months of treatment will be reported.
Time frame: Approximately 24 months
Ran from Aug 2018 to primary completion in May 2021, 33 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Janssen-Cilag Farmaceutica Ltda. →